In September 2000, Dr. Shrotriya joined the Company as President and Chief Operating Officer and in August 2002, he was appointed Chief Executive Officer. In this capacity he has spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc.
Previously, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research.
Dr. Sandler is responsible for all medical affairs, regulatory, and clinical operations for the Company's portfolio of drug candidates.
Dr. Sandler has a broad-based experience in Phase I, I/II, II, III, IIIb, IV and all post-marketing studies and activities. He was also responsible for the medical development and launch activities of CAMPATH® in first-line CLL, FLUDARA®, LEUKINE®, NEXAVAR® in HCC, and ZEVALIN®. Dr. Sandler was most recently the Vice President and head of Global Medical Affairs in the Oncology division of Bayer Healthcare Pharmaceuticals. At Bayer, he supervised all commercial input into clinical development plans, and provided strategic direction to all of Bayer's marketed, pre-launch, and immediate post-launch products. From 2003-2006, Dr. Sandler was at Berlex Oncology, most recently as the Head of Global Medical Affairs, where he led and contributed to the development of lifecycle management plans, provision of continuous risk/benefit assessment, support in the Labeling and Protocol review process and, initiation, planning and approval of studies. From 1999-2003, Dr. Sandler was the Director of Clinical Development for Seattle Genetics, where he oversaw the strategic planning and clinical operations of the Phase 1 and Phase 2 studies, and participated in two IND submissions. Dr. Sandler received his BS in Neuroscience from the University of Rochester in New York, his MD from Mount Sinai School of Medicine in New York, his internship, residency, and chief residency at the Mount Sinai Hospital in New York, and his Fellowship in Medical Oncology from the University of California-San Francisco.
Amar Singh , MBA
Chief Commercial Officer
Mr. Singh is responsible for aspects of sales and marketing, business development, and investor and public relations.
Mr. Singh has more than 25 years of experience in the pharmaceutical industry with increasing responsibilities throughout his career. Mr. Singh was most recently the Chief Commercial Officer for Novacea, where he was responsible for commercialization and business development. Prior to Novacea, Mr. Singh served as Vice President of Marketing and Sales at Abraxis Oncology, a proprietary division of American Pharmaceutical Partners, Inc., where he was responsible for building the branded division that launched Abraxane. Mr. Singh served in multiple capacities at Roche Laboratories, a Division of Hoffmann La Roche, where he held positions in Market Research, Licensing and Business Development, New Product Planning, and Marketing. From 2000 to 2003, he was Executive Director for Oncology Marketing and subsequently for New Product planning for the Specialty Care business, where he led the launches of XELODA®, a novel oral chemotherapeutic agent for the treatment of metastatic breast cancer, and KYTRIL®, an anti-nausea agent used in combination with oncolytics.
Mr. Singh holds a B.A. in Economics from the University of North Carolina Chapel Hill, and an MBA from New York University.
Shyam Kumaria , C.P.A.
Vice President, Finance
Shyam Kumaria brings to Spectrum over 30 years of financial, accounting, and operations management experience serving public and private companies in a variety of industries. Mr. Kumaria's career spans more than two decades at Deloitte & Touche, the international public accounting and consulting firm. As a Senior Manager in the middle-market group of Deloitte & Touche, in Los Angeles, he led over 20 mergers and acquisitions and initial public offerings for client companies. Over the course of his career he has served public and private companies ranging in size up to $1 billion in revenue including, among others, the healthcare, technology, and financial services industries.
In addition, Mr. Kumaria spent ten years providing strategic finance, accounting, and business process consulting services to small companies in turnaround and growth modes; most recently at The Finance and Accounting Connection, Inc., where he provided interim and project-based financial services to client companies.
Mr. Kumaria holds an Executive MBA from Columbia University. He is a member of the American Institute of Certified Public Accountants, the California Society of CPA's, and is a fellow of the Institute of Chartered Accountants in England and Wales.
Dr. Adam has 23 years drug development experience. He was most recently the Senior Vice President, Drug Development Operations at Anadys Pharmaceuticals, Inc. He had primary responsibility for regulatory affairs, quality assurance, pharmaceutical development, manufacturing, and project management. Prior to Anadys, Dr. Adam was Vice President, Pharmaceutical Sciences at in the Global Research & Development division of Pfizer, Inc. At Pfizer he led the La Jolla, California organization responsible for chemical, analytical and pharmaceutical development from compound identification through launch and product enhancement. Prior to Pfizer, Dr. Adam was Vice President, of Worldwide Regulatory Affairs, Quality Assurance and Compliance at Agouron Pharmaceuticals. He was responsible for the firm's Regulatory CMC group. Prior to Agouron, Dr. Adam was the Director of Worldwide Regulatory Affairs, CMC Group, at Bristol-Myers Squibb, where he managed Regulatory CMC projects in CNS and CV/MD therapeutic areas. Dr. Adam earned his Ph.D. in Organic Chemistry at the Massachusetts Institute of Technology in Cambridge, MA. Dr. Adam also holds an Entrepreneur-in-Residence at CONNECT helping pharmaceutical/biotech start-ups.
George Uy
Vice President, Marketing & Sales
George brings more than 20 years of hands on experience in both large and small pharmaceutical companies. His experience includes leadership roles in oncology marketing at Roche and Abraxis BioScience, in the U.S., Switzerland, China and the Philippines.
George is currently designing and implementing marketing strategies for drugs that are in regulatory review and in the late stages of development. In addition he will play an important role in identifying in-licensing and partnership opportunities with late stage drugs.
While at Abraxis, as Executive Director of Marketing, he oversaw the strategic and tactical launch of Abraxane in 2005 for the treatment of metastatic breast cancer. Abraxane attained over $130 million in sales in its 2005 launch year. Prior to Abraxis, George spent 23 years of increasing management experience at Roche, most recently serving as the U.S. Brand Director for Xeloda where he was responsible for the successful 2001 launch of Xeloda in colorectal cancer and advanced breast cancer. During his tenure at Roche, George was involved in the launch of several key Roche products not only in the U.S., but worldwide.
William Pedranti , Esq.
Vice President, General Counsel
Mr. Pedranti is the head of legal affairs for Spectrum Pharmaceuticals. He has a J.D. from Georgetown University Law Center and a B.S. in Business-Entrepreneurship from the University of Southern California.
Mr. Pedranti came to us from Latham & Watkins LLP, where he represented Spectrum on a number of matters. As a corporate associate at Latham, Mr. Pedranti focused his practice on securities law and general public company representation work.
Luigi Lenaz , M.D.
Former Chief Scientific Officer, now consultant for Spectrum Pharmaceuticals, Inc.
show all
hide all
